Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma
1 Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Oxford, OX3 7LJ, UK
2 MRC Clinical Trials Unit, London, NW1 2DA, UK
3 Cambridge Biomedical Research Centre, Cambrige, CB2 0QQ, UK
4 Department of Cellular Pathology, John Radcliffe Hospital, Headington, OX3 9DU, UK
5 Department of Gastroenterology, John Radcliffe Hospital, Headington, Oxford, OX3 9DU, UK
BMC Cancer 2012, 12:590 doi:10.1186/1471-2407-12-590Published: 11 December 2012
Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort.
Here we report an idiosyncratic reaction to sorafenib resulting in fatal hepatotoxicity and associated renal failure in a 62 year-old man treated with sorafenib within the SORCE trial.
This is the first reported case of sorafenib exposure associated fatal toxicity in the adjuvant setting and highlights the unpredictable adverse effects of novel adjuvant therapies.